Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Hubbard retires

This article was originally published in The Tan Sheet

Executive Summary

Randall Lutter, PhD, has been named Associate Commissioner for Policy & Planning following the retirement of William Hubbard, FDA says March 4. Hubbard is leaving the agency after "a long, distinguished career in the federal government," which included stints at OMB and the President's Council of Economic Advisors. During his tenure at FDA, Hubbard was "a major originator" of the OTC label redesign and PDUFA. Lutter joined FDA in 2002 as chief economist in the Office of Planning; he will serve as a senior advisor to Acting Commissioner Crawford, with special attention to the "public policy implications of FDA's regulatory and administrative activities"...

You may also be interested in...

Amneal Wins Race For US NuvaRing Rival

Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts